Literature DB >> 10651223

CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity.

S Sato1.   

Abstract

The CD19/CD21 complex is categorized among the 'response regulator' class of receptors which determine the magnitude and outcomes of B cell receptor signals. Small changes in CD19 expression have dramatic effects on signaling thresholds within B cells, which in turn has considerable impact on the balance between humoral immune responses and tolerance induction. B cell signaling thresholds lowered by increased CD19 expression may significantly augment host susceptibility to the development of autoimmunity. Signals generated by C3d-antigen complex binding to CD21 may also be involved in the development of autoimmunity by regulating CD19 function. Since CD19 serves as a central regulator of signaling thresholds in B cells, the CD19/CD21 complex may be an appropriate target for suppressing the development of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10651223     DOI: 10.1016/s0923-1811(99)00043-2

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  4 in total

1.  The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development.

Authors:  Alexandra I Ziegler; Melanie A Le Page; Mhairi J Maxwell; Jessica Stolp; Haoyao Guo; Abhirup Jayasimhan; Margaret L Hibbs; Pere Santamaria; Jacques F Miller; Magdalena Plebanski; Pablo A Silveira; Robyn M Slattery
Journal:  Diabetologia       Date:  2013-09-08       Impact factor: 10.122

2.  Dysregulated PI3K Signaling in B Cells of CVID Patients.

Authors:  Ina Harder; Matthias Münchhalfen; Geoffroy Andrieux; Melanie Boerries; Bodo Grimbacher; Hermann Eibel; Maria Elena Maccari; Stephan Ehl; Jürgen Wienands; Julia Jellusova; Klaus Warnatz; Baerbel Keller
Journal:  Cells       Date:  2022-01-28       Impact factor: 6.600

Review 3.  Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.

Authors:  Eyal Lebel; Boaz Nachmias; Marjorie Pick; Noa Gross Even-Zohar; Moshe E Gatt
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

4.  CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

Authors:  Kemeng Wang; Guoqing Wei; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2012-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.